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Abstract
Objectives: The role of positron emission tomography (PET) with fluoro-deoxy-glucose (FDG) in the staging of
head and neck cancer (HNC) is unclear. The NCCN guidelines do not recommend FDG-PET as a part of standard
workup. The purpose of this report is to examine the role of FDG-PET imaging in altering management and
providing prognostic information for HNC.
Methods: Retrospective review of HNC patients who had a staging FDG-PET scan performed at either Thomas
Jefferson University or University of Kansas Medical Center between the years 2001 and 2007. A total of 212 PET
scans were performed in patients who went on to receive radiotherapy.
Results: The median follow-up time for all patients was 469 days. The PPV and NPV of PET imaging to correctly
identify lymph node status was 94% and 89% respectively. Lymph nodes with extracapsular extension (ECE) had
higher SUVs than nodes without ECE, 11.0 vs. 5.0 (p < 0.0007). Maximum SUV for the primary tumor > 8.0 was
predictive of worse overall survival (p < 0.045), while the SUV of the lymph nodes was predictive for distant
recurrence at one year–with a mean SUV value of 10.4 for patients with distant failure vs. 7.0 without (p < 0.05).
Conclusions: FDG-PET staging in head and neck cancer has good positive and negative predictive values in
determining lymph node status. The maximum SUV of the primary tumor is predictive of overall survival. This is the
first report to find that the SUV of a lymph node is predictive for ECE and also for distant recurrence.
Introduction
Approximately 47,500 new cases of head and neck can-
cer (HNC) are diagnosed annually in the United States
[1], the cure rates for HNC, especially in advanced dis-
ease, remains poor [2]. Because of this there have been
efforts to improve outcomes through the use of targeted
agents [3], new radiation techniques such as intensity
modulated radiation therapy (IMRT) and image guided
radiation therapy (IGRT), as well as new types of diag-
nostic imaging. Scanning utilizing FDG has become
standard of care for many malignant neoplasms [4] for
its ability to more accurately stage tumors, and thus
alter therapeutic decision making, compared to conven-
tional imaging modalities such as computed tomography
(CT) and magnetic resonance imaging (MRI).
The use of FDG-PET scanning in head and neck can-
cer is more controversial. NCCN guidelines do not
include PET scans as part of routine staging, and many
institutions use MRI or ultrasound guided biopsies
rather than PET scans. The Radiation Therapy Oncology
Group (RTOG) utilizes the clinical exam, chest x-ray,
and pre-treatment CT scan as their standard workup.
Despite the lack of acceptance of staging PET scans
into guidelines and cooperative groups, there are a num-
ber of studies that have examined the role of PET scans
in HNC staging. Several studies [5-8] have looked at the
value of PET in initial staging and the finding of meta-
static disease or secondary cancers; the incidence seen
in some of the larger studies [7,8] is 11.1 to 12.9%. The
staging of lymph node status with PET has also been
examined [5,9-17]; the sensitivity of PET in this regard
ranges from 47 to 100% while the specificity ranges
from 87 to 100%.
The prognostic value of SUVs is another unresolved
issue with PET scanning. In theory, a greater SUV
would correspond with a more aggressive tumor. While
some authors [18-24] have found a relationship between
* Correspondence: greg.kubicek@gmail.com
1Thomas Jefferson University Hospital, Philadelphia, PA, USA
Kubicek et al. Head & Neck Oncology 2010, 2:19
http://www.headandneckoncology.org/content/2/1/19
© 2010 Kubicek et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.maximum tumor SUV and clinical outcome, others
[25,26] have not found this to be true. A few reports
have examined the role of nodal SUV and outcome
[18,19,27], with inconclusive results. Having prognostic
information, especially in terms of patterns of failure,
would be very useful. If there was a way to determine
which patients had a greater risk of distant failure versus
local failure, clinicians wou l db ea b l et od e t e r m i n ew h o
would be ideal candidates for induction chemotherapy.
One of difficulties in interpreting the large number of
studies on the topic of PET scans in the staging of HNC
is the low number of patients in any one study. To
increase the patient numbers we have combined the
databases of two institutions with high-volume HNC
services. This allows for better assessment of the cap-
abilities of PET scans for staging HNC.
Methods
This is a retrospective review of PET scans used in
staging at two academic institutions; Thomas Jefferson
University Hospital (Philadelphia, PA) and the Kansas
University Medical Center (Kansas City, KS). Prior to
beginning the review, approval was granted from the
institutional review board (IRB) of each institution.
Using the PET scan registry of both institutions, all of
the PET scans for HNC that had been performed
from 2000 to 2007 were analyzed. Patients who went
on to have adjuvant or definitive radiotherapy with or
without chemotherapy were included in the final
analysis.
Images were acquired with either a PET or PET
coupled with a low energy CT utilized for attenuation
correction (CTAC) of the PET data. PET scans per-
formed at Thomas Jefferson University Hospital used a
Siemens Biograph 6 (Siemens Medical Solutions USA,
Inc, Malvern, PA). For the PET/CTAC images, the CT
component was a GE Lightspeed, 16 slice scanner (Gen-
eral Electric, Milwaukee, WI). Kansas University Medical
Center used a Siemens ECAT ART (Advanced Rota-
tional Tomograph) and a GE Discovery ST 16 slice
scanner. Imaging protocols were similar at both institu-
tions. Before the PET scan, all patients were required to
fast for four hours, and blood glucose had to be less
than 180 mg/dl. Ten to 15 mCurie (370-555 MBq) of
(18F)-FDG was injected and 45 to 60 minutes was
allowed for uptake before patient imaging. Patients were
instructed to minimize any talking, chewing, swallowing,
or movement of the head.
For fused PET/CT images, the CTAC and PET images
were hardware coregistered in a single session. Non-
contrast-enhanced CT imaging for attenuation correc-
tion and anatomic correlation was performed first from
the vertex of the skull to below the kidneys. First the
CT scan was completed using 180-mA tube current,
140-kV tube voltage, 0.5-second tube rotation, helical
pitch of 1:1, and reconstructed slice thickness of
4.25 mm. The CT portion was acquired in less than
30 seconds. Immediately after the CT scan, a PET scan
was acquired starting at the skull vertex with an acquisi-
tion time of 5 minutes per bed position with a one-slice
overlap at the borders of the 14.6-cm field of view. Data
were reconstructed using OSEM iterative reconstruction
with two iterations and 28 subsets. Post-processing with
a post filter at 5.45 mm full width at half maximum
(FWHM), and a loop filter at 3.91 mm FWHM on a 128
× 128 matrix was then carried out. Images were viewed
on a Xeleris (GE medical Systems) workstation. For
scans that did not have CT fusion, the PET scan data
was read in conjunction with other radiology exams (for
example CT scan or MRI) if available.
Interpretation of the images consisted of reviewing the
nuclear medicine report, information was gathered con-
cerning areas of increased uptake and, if available, the
maximum SUV. Radiology review was performed inde-
pendently of reviewing the clinical chart. Clinical infor-
mation was obtained from a retrospective chart review.
Analysis was performed after all of the pertinent clinical
and radiographic information had been gathered. Statis-
tical analysis was performed using Graphpad (GraphPad
Software Inc. La Jolla, CA) software.
Results
A total of 212 patients (212 PET scans) were analyzed in
this study, patient characteristics are outlined in Table 1.
The majority of patients had advanced HNC, 80.2%
were either stage III or IV. The median follow-up for all
patients was 469 days with a range of 40 to 1596 days
as measured from the end of radiation.
SUVs were available for 152 of the masses and 79 of
the lymph nodes, 52 patients did not have a reported
SUV (results for these patients were reported as positive
or negative). The median maximum SUV was 8.75 with
a range of 1 to 41 for the main tumor mass. The med-
ian maximum SUV was 5.95 with a range of 2 to 25 for
the lymph node, when multiple lymph nodes were
found, only the lymph node with the highest SUV was
used.
At last follow-up, 119 patients were still alive; Kaplan-
Meier median overall survival for the entire cohort was
886 days, Kaplan-Meier median disease free survival for
entire cohort was 726 days. When SUV of the tumor
mass was analyzed in terms o fo v e r a l ls u r v i v a lu s i n g
log-rank (Mantel-Cox) test, it was found that SUV > 8
was statistically significant for a worse overall survival
(p < 0.045) with an overall survival of 669 days for
patients with an SUV of the mass greater than 8 and a
median overall survival of 984 days for patients with a
SUV of the mass less than 8. Figure 1.
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Page 2 of 7Seventy-eight patients had a recurrence, 35 distant and
43 local, with a median time to recurrence of 135 days.
One hundred and thirty one (61.7%) had local control
with no evidence of disease at last follow-up or at time
of death from non-cancer causes. Twenty patients had
persistent disease after radiation, 5 of these patients had
distant recurrence as well. There was a trend for
patients with an SUV of the mass ≤8t oh a v ei m p r o v e d
local control, but this did not reach statistical signifi-
cance (p = 0.16) Figure 2. The maximum lymph node
SUV was found to be predictive for distant failure
(p < 0.0001), but not for overall or local failure. Median
lymph node SUV was 10.0 for patients with distant fail-
ure vs. 5.2 without. Figure 3.
One hundred and ten patients had a neck dissection
performed after the PET scan prior to radiotherapy.
PET scan in these patients was obtained a median of
12 days prior to the surgical neck dissection (range 3 to
91 days). For these 110 patients, the radiographic lymph
node status was compared to the final surgical pathol-
ogy. Four false positives and 5 false negatives were
found giving a sensitivity of 92.5%, specificity of 90.7%,
positive predictive value (PPV) of 93.9% and a negative
predictive value (NPV) of 88.6%. Of the 5 false negative
PET scans, there was 1 T1 base of tongue cancer, 1 T2
p a r o t i d ,1T 2o r a lt o n g u e ,a n d2T 4o r a lc a v i t y .A l l
patients with a false negative PET scan had one lymph
node positive for metastatic disease found on subse-
quent neck dissection. For the false positive results,
there was 1 T2 oral tongue, 1 T4 oral cavity, 1 T4 lar-
ynx, and 1 T2 tonsil. Neck dissections for the 4 false
positive PET scans showed no positive lymph nodes
with a median of 23 (range 9 to 27) nodes dissected.
Twenty-two patients had ECE of a lymph node found
on neck dissection; fifteen of these patients had reported
SUV of the lymph node. The median SUV of these
lymph nodes was 11.9 versus 5.0 for lymph nodes with-
out ECE, which was significantly different (p < 0.0007)
on a student’s T-test. ECE was found in 6 patients with
N1 nodal disease and 16 patients with N2-3 nodal dis-
ease. On a repeated measures ANOVA, there was no
difference in median SUV of the lymph node based on
nodal status (N1 versus N2-3).
Table 1 Patient Characteristics
Characteristic Total KUMC Thomas Jefferson
Total 212 92 120
Gender
Male 124 69 55
Female 88 23 65
Age (median, years) 58 58 56
Tumor Site
Oral cavity 29 17 12
Oropharynx 89 39 50
Larynx 54 29 25
Hypopharynx 3 2 1
Salivary Gland 13 2 11
Nasal-Sinus 9 1 8
Unknown primary 5 1 4
Stage
T0 13 6 7
T1-2 66 28 38
T3-4 120 58 62
Recurrent 13 0 13
N0 78 28 50
N1 36 18 18
N2-3 98 46 52
Chemotherapy 159 59 100
Surgical resection 42 18 24
Figure 1 Kaplan Meier Overall Survival. Figure 1 shows overall survival by mass SUV greater and lesser than 8. Curves are significantly
different (p < 0.045).
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a PET/CT scan in 93 patients. For the 110 patients with
post-PET neck dissections, 55 had PET-CT scans and
55 had PET scans. When analyzed for any differences
between the imaging modalities by nodal staging, PET/
CT scans had 2 false positive results and 0 false nega-
tives while PET without CT fusion had 2 false positives
and 5 false negatives. The sensitivity for the PET/CT
was 100% with a specificity of 90.1% and a PPV of 94%
and NPV of 100%. For PET alone, the sensitivity was
85.7%, specificity 90%, PPV of 93.4% and NPV of 78.2%.
Using a student’s T-test, PET and PET/CT were not sta-
tistically significantly different in overall ability to deter-
mine lymph node status (p = 0.089).
Discussion
Several recent innovations have been introduced in
efforts to improve the clinical outcome in the treatment
of HNC. New radiotherapy technologies such as IMRT
and IGRT have improved radiotherapy delivery and new
surgical techniques including sentinel lymph node
biopsy also have potential for improving HNC therapy.
In addition, increased implementation of diagnostic
exams such as PET and PET/CT scans have the poten-
tial to improve treatment outcomes by providing
improved lymph node staging, prognostic, and perhaps
predictive factors.
W ef o u n de x c e l l e n tp o s i t i v ea n dn e g a t i v ep r e d i c t i v e
value for PET scans in determining lymph node status.
This finding is in line with several other reports
[5,9-17]. Table 2. These findings have potential clinical
implication in that it may be possible to use staging
PET scan results in stratifying patients who should go
on to receive neck dissections. Ng et al. [11] found
false negative PET scan results depended on the T
stage of the tumor with false negative PET scans in
Figure 2 Kaplan Meier Disease Free Survival. Figure 2 represents disease free survival by mass SUV greater and lesser than 8. The curves are
not statistically significantly different (p = 0.16).
Figure 3 Kaplan Meier Time to Distant Recurrence. This graph shows time to distant recurrence with nodal SUV greater to and lesser than
10. The curves are statistically significantly different (p < 0.011).
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Page 4 of 76.7, 10.8, 13.3, and 25% for T1-4 tumors respectively.
Our results also demonstrate the low false negative
rate in staging PET scans, although we did not find a
relation between T stage and false negative rates, likely
secondary to the low number of false negative PET
scans. A recent meta-anaylsis [28] examining the
results of PET scan in cervical lymph node staging
found lower sensitivity (79%) and specificity (86%)
results than our study. Some explanations for this
include the fact that most of the studies in the meta-
analysis were older and used PET scan alone rather
than combined PET/CT.
Several authors have examined if PET/CT is superior
to PET alone in nodal staging [29-31]. Bransetter et al.
[30] reported that PET/CT was superior to PET alone
in HNC lesions, and Schoder et al. [32] arrived at the
same conclusion. The overall accuracy in determining
lymph node status was not statistically significantly bet-
ter for PET/CT in this study, but there was a trend
towards significance. Although PET/CT had several
false-positive results there were no false negatives. The
added accuracy of CT fusion with the PET scan, espe-
cially in terms of reducing the number of false negative
scans, is important in the use of PET/CT to limit surgi-
cal neck dissection.
This report and others can help determine the best
use for PET scans in the nodal staging of HNC. Our
report lends strength to the previously published stu-
dies regarding the excellent predictive value of PET
scans in determining lymph node status. Having ade-
quate knowledge of lymph node status without the aid
of surgical dissection has several potential areas of
clinical benefit. Neck dissections add significant mor-
bidity in HNC patients [33] and PET scans may be
able to determine which patients do not require a full
dissection. If further evidence, perhaps in the form of a
prospective trial, can confirm the accuracy of PET
scans in lymph node staging, it would be possible to
use imaging in lieu of surgery for determining lymph
node status.
The role of maximum SUV as a prognostic factor is
controversial. Several reports have found a particular
SUV value associated with a worse outcome [18-24].
However, other authors did not report this association
[26,27]. One factor in the mixed findings of maximum
SUV and outcome may be related to the relatively small
number of patients in many of these studies. Our data
found that SUV of the tumor mass > 8 was associated
with worse overall survival. Interestingly, we did not
find an association between tumor mass SUV and local
control, likely secondary to several late relapses. Fewer
reports have focused on the prognostic information of
nodal SUV. Schwartz et al. [19] did not find any associa-
tion between nodal SUV and outcome in 36 patients,
Brun et al [20] also failed to find any association and
also had 36 patients. Liao et al. [27] examined only oral
cavity patients with positive lymph nodes and found
that a lymph node SUV of 5.4 predicted for worse out-
comes. We found an association between maximum
SUV of the lymph node and outcome with nodal SUV >
10 more likely to have distant failure in 79 patients with
nodal SUV. One explanation of the discrepancy between
our data and that of Schwartz et al. and Brun et al.
could be the larger number of patients which would
give our study power to detect a true finding.
Although prognostic information, such as tumor mass
SUV, is useful, it is not used for management changes.
However, the association between maximum lymph
node SUV and distant failure has possible clinical impli-
cations. One of the current trends (although still unpro-
ven) in HNC is neoadjuvant chemotherapy with TPF
[34,35]. If further reports confirm the finding that maxi-
mum lymph node SUV > 10 has a higher likelihood of
distant failure but not a higher likelihood of local failure,
this would be a possible stratification factor for which
patients should receive neoadjuvant TPF rather than
concurrent therapy.
We also found that maximum SUV was predictive of
ECE. ECE is an established risk factor and is one of the
indications (the other being positive margins) in deter-
mining which patients post-operatively benefit from
combined chemoradiotherapy rather than radiotherapy
alone [36]. For patients receiving definitive radiotherapy,
it may make be beneficial to treat higher SUV lymph
nodes (which are more likely to harbor ECE) to a higher
dose.
The results of this study need to be interpreted with
caution; it is retrospective in nature and includes a vari-
ety of head and neck cancer subtypes. In this regard,
our study has the same flaws as the majority of other
reports examining the utility of FDG-PET in the staging
of head and neck cancer. However, this study does have
some improved clinical utility secondary to its size (212
PET scans analyzed) and the multi-institution nature of
Table 2 Results for Staging with PET
Study Patients Sensitivity Specificity
Murakami (8) 23 79 99
Ng (10) 134 47 92
Fleming (17) 67 86 94
Hannah (11) 48 82 100
Schwartz (15) 20 100 96
Zanation (4) 97 93 89
Roh (21) 167 87 93
Kyzas (28) 1236 79 86
Kubicek* 110 93 91
* Current Study
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tion gathered are hypotheses generating and that further
studies, perhaps in a prospective randomized fashion,
will be required to truly determine the utility for PET
scans in HNC. Until such studies are completed, large
retrospective such as this are needed to provide the best
information at this time possible.
Conclusions
FDG-PET scanning has good accuracy and predictive
value in determining lymph node status. SUV of the
tumor mass is prognostic for overall survival. SUV of
the lymph node is prognostic for ECE and also for dis-
tant recurrence. Patients with higher lymph node SUVs
treated with definitive radiation may warrant higher
radiotherapy doses to overcome a greater likelihood of
ECE. Nodal SUV may be used to predict patients who
would be more likely to benefit from induction
chemotherapy.
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